References

zdor

Проблемы здоровья и экологии

Health and Ecology Issues

2220-09672708-6011

Gomel State Medical University

10.51523/2708-6011.2009-6-4-2

zdor-876

Research Article

КЛИНИЧЕСКАЯ МЕДИЦИНА

CLINICAL MEDICINE

ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ (обзор литературы, часть I)

THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I)

Саливончик

Д. П.

Salivonchik

D. P.

noemail@neicon.ru

Гомельский областной клинический кардиологический диспансерGomel Regional Clinical Cardiologic Dispensary

2009

28122009

041218

2009

Саливончик Д.П.

Salivonchik D.P.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.gsmu.by/jour/article/view/876

В 4 частях обзора представлена информация о современной терапии острого коронарного синдрома (ОКС).

The information about the modern medical treatment of the acute coronary syndrome was presented in the fours parts of this review.

острый коронарный синдроминфаркт миокарданестабильная стенокардияacute coronary syndromemyocardial infarctionunstable angina

References1

ACC/AHA Guideline Update for the Management of Stable Angina and Non-ST-Segment Elevation Myocardial Infarction - 2002: Summary Article: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) // Circulation. - 2002. - Vol. 106. - P. 1893-1900.

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) / E. M. Antman [et al.] // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 211.

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) // Circulation. - 2006. - Vol. 113. - P. 156-175.

Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative / T. J. Meine [et al.] // Am. Heart J. - 2005. - Vol. 149. - P. 1043-1049.

Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the CUSTO-I experience Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries / M. Pfisterer [et al.] // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 634-640.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial / P. A. Poole-Wilson [et al.] // Lancet. - 2003. - Vol. 362. - P. 7-13.

Routine use of oxygen in the treatment of myocardial infarction: Systematic review / M. Wijesinghe [et al.] // Heart. - 2009. - Vol. 95. - P. 198-202.

Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction / J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 1-157.

Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial / J. A. de Lemos [el al.] // J.A.M.A. - 2004. - Vol. 292. - P. 1307-1316.

Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial / S. Nissen [et al.] // J.A.M.A. - 2004. - Vol. 291. - P. 1071-1080.

Effects of Atorvastatine on Early Reccurents Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Trial / G. G. Schwartz [et al.] // J.A.M.A. - 2001. - Vol. 285. - P. 1711-1718.

Hear Protection Collaborative Group MRC/BNF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individual: a randomized placebo-controlled trial / Lancet. - 2002. - Vol. 360. - P. 7-22.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines / S M. Grundy [et al.] // Circulation. - 2004. - Vol. 110. - P. 227-239.

Intensive versus moderate lipid lowering with statins after acute coronary syndromes / C. P. Cannon [et al.] // N. Engl. J. Med. - 2004. - Vol. 350. - P. 1495-1504.

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy / C. P. Cannon [et al.] // J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P. 438-445.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1349-1357.

Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality / J. B. Muhlestein [et al.] // Am. J. Cardiol. - 2001. - Vol. 87. - P. 257-261.

Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-Dose Atorvastatin vs. Usial-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial / T. R. Pedersen [et al.] // J.A.M.A. - 2005. - Vol. 294. - P. 2437-2445.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) // Lancet. - 1994. - Vol. 344. - P. 1383-1389.

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1349-1357.

Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) / A. M. Gotto [et al.] // Circulation. - 2000. - Vol. 101. - P. 477-484.

Беленков, Ю. Н. Кардиология. Национальное руководство / Ю. Н. Беленков, Р. Г. Оганов. - М.: Геотар-Медиа, 2007. - 1232 с.

Antiatherotrombotic properties of statins: implications for cardiovascular event reduction // J.A.M.A. - 1998. - Vol. 279. - P. 1643-1650.

Benefits of Lipid Lowering on Vascular Reactivity in Patients with Coronary Artery Disease and Average Cholesterol Levels: A Mechanism for Reduction Clinical Events? / J. D. Cohen [et al.] // Am. Heart J. - 2000. - Vol. 139. - P. 734-738.

Effect of early treatment with statins on short-term clinical outcomes in acute coronary syndrome: a meta-analysis of randomized controlled trials / M. Briel [et al.] // J.A.M.A. - 2006. - Vol. - 295. - P. 2046-2056.

For the Asteroid Investigators. Effect of Very High-Intensity Statin Therapy in Regression of Coronary Atherosclerosis: The ASTEROID Trial / T. J. Nissen [et al.] // JAMA. - 2006. - Vol. 295. - P. 1556-1565.

ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58050 patients with myocardial infarction // Lancet. - 1995. - Vol. 345. - P. 669-685.

Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardio GISSI-3: effects of lisinopril and transdermal glyceril trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction // Lancet. - 1994. - Vol. 343. - P. 669-685.

Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study / L. K. Newby [et al.] // Circulation. - 2001. - Vol. 103. - P. 1832-1837.

Beta blocade after myocardial infarction: systematic review and meta-regression analysis / N. Freemantle [et al.] // B.M.J. - 1999. - Vol. 32. - P. 634-640.

Dargie, H. J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial / H. J. Dargie // Lancet. - 2001. - Vol. 537. - P. 1385-1390.

Early intravenous then oral metoprolol in 45.852 patients with acute myocardial infarction: randomized placebo-controlled trial / Z. M. Chen [et al.] // Lancet. - 2005. - Vol. 366. - P. 1622-1632.

Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport trials / K. Ellis [et al.] // J. Interv. Cardiol. - 2003. - Vol. 16. - P. 299-305. 33а. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials / S. Yusuf [et al.] // J. Hypertens. - 1993. - Vol. 11, № 4. - Р. 61-73.

Danish Verapamil Infarction Trial (DAVIT) Study Group Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone / J.F. Hansen [et al.] // Am. J. Cardiol. - 1997. - Vol. 79. - P. 738-741.

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomized placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Trombolysis / W. E. Boden [et al.] // Lancet. - 2000. - Vol. 355. - P. 1751-1756.

Updata of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies / S. Yusuf [et al.] // Am. J. Cardiol. - 1991. - Vol. 67. - P. 1295-1297.

ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials // Circulation. - 1998. - Vol. 97. - P. 2202-2212.

The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years / P. Buch [et al.] // Eur. Heart J. - 2005. - Vol. 26. - P. 145-152.

Effect of an angiotensin-converting-enzime inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators / S. Yusuf [et al.] // N. Engl. J. Med. - 2000. - Vol. 342. - P. 145-153.

Long-term ACE-inhibitor therapy in heart failure or left-ventricular dysfunction: a systemic overview of data from individual patient / M. D. Flather [et al.] // Lancet. - 2000. - Vol. 355. - P. 1575-1581.

The BARI Investigators Seven-year outcome in the Bypass Angioplasty revascularization Investigation (BARI) by treatment and diabetic status // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 1122-1129.

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study / Z. Zuanetti [et al.] // Circulation. - 1997. - Vol. 96. - P. 4239-4245.

Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review / K. K. Teo [et al.] // Lancet. - 2002. - Vol. 360. - P. 1037-1043.

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of there trials / G. R. Dagenais [et al.] // Lancet. - 2006. - Vol. 368. - P. 581-588.

Fox, K. M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study) / K.M. Fox // Lancet. - 2003. - Vol. 362. - P. 782-788.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program / M. A. Pfeffer [et al.] // Lancet. - 2003. - Vol. 362. - P. 759-766.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction / B. Pitt [et al.] // N. Engl. J. Med. - 2003. - Vol. 348. - P. 1309-1321.

Randomized Aldactone Evaluation Study Investigators The Effect of spironolactone on morbidity and mortality in patients with severe heart failure / B. Pitt [et al.] // Engl. J. Med. - 1999. - Vol. 341. - P 709-717.

The Working Group on Neurocardiology Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris / I. A. Ten Vaarwerk [et al.] // Heart. - 1999. - Vol. 82. - P. 82-88.

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial / D. A. Morrow [et al.] // JAMA. - 2007. - Vol. 297. - P. 1775-1783.

Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation / Jr. Holmes [et al.] // Circulation. - 1999. - Vol. 100. - P. 2067-2073.

Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry / G. W. Stone [et al.] // J. Am. Col. Cardiol. - 2003. - Vol. 41. - P. 1940-1945.

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherotrombosis? Meta-analysis of randomized trials / P. M. Kearney [et al.] // B.M.J. - 2006. - Vol. 332. - P. 1302-1308.

For the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction / E. M. Antman [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1477-1488.

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) / W. Klein [et al.] // Circulation. - 1997. - Vol. 96. - P. 61-68.

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial / S. Yusuf [et al.] // J.A.M.A. - 2006. - Vol. 295. - P. 1519-1530.

Enoxaparion versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction / E. M. Antman [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1477-1488.

Antitrombotics Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // B.M.J. - 2002. - Vol. 324. - P. 71-86.

Antithrombotic Therapy in Acute Coronary Syndromes Research Group Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial Circulation / M. Cohen [et al.] // Circulation. - 2004. - Vol. 89. - P. 81-88.

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease: Antithrombotic Therapy Consortium Inverstigators / R. C. Becker [et al.] // Am. Heart J. - 1999. - Vol. 137. - P. 59-71.

The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease / E. M. Ohman [et al.] // J. Thromb. Thrombolysis. - 2005. - Vol. 19. - P. 11-19.

Hirsh, J. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy / J. Hirch, R. Raschke // Chest. - 2004. - Vol. 126. - P. 188-203.

The authors declare that there are no conflicts of interest present.